Back to Search
Start Over
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.
- Source :
-
Journal of asthma and allergy [J Asthma Allergy] 2018 Mar 23; Vol. 11, pp. 29-39. Date of Electronic Publication: 2018 Mar 23 (Print Publication: 2018). - Publication Year :
- 2018
-
Abstract
- Background: Bepotastine besilate ophthalmic solution (BBOS) 1.5% is a topical antihistamine for the treatment of ocular itching associated with allergic conjunctivitis (AC). Allergic rhinitis and AC are common comorbid conditions. We explored the efficacy of BBOS 1.5% in alleviating nasal symptoms in an integrated analysis of two Phase III conjunctival allergen challenge (CAC) studies and a Phase IV environmental allergen study.<br />Methods: In the Phase III trials, a CAC was performed 15 minutes, 8 hours, and 16 hours following ocular instillation of BBOS 1.5% (n=78) or placebo (n=79), and subjects evaluated nasal symptoms. In the environmental study, subjects instilled BBOS 1.5% (n=123) or placebo (n=122) twice daily and nasal symptoms were evaluated over 2 weeks.<br />Results: In the Phase III trials, BBOS 1.5% had reduced CAC-induced nasal congestion and pruritus at 15 minutes and 8 hours postdosing and rhinorrhea and a non-ocular composite-symptom score (sum of nasal scores plus ear or palate pruritus) at all time points postdosing (all P ≤0.01 vs placebo). In the Phase IV environmental study, BBOS 1.5% reduced sneezing and nasal pruritus over 2 weeks and median number of days to improvement of nasal pruritus and total nasal symptom score (sum for rhinorrhea, sneezing, nasal pruritus, and nasal congestion; P ≤0.04 vs placebo). Additionally, investigator-reported improvement in overall ocular (pruritus, hyperemia, tearing) and nasal symptoms was greater with BBOS 1.5% vs placebo ( P ≤0.03).<br />Conclusion: Results of these exploratory analyses indicate that topical ocular BBOS 1.5% reduced nasal symptoms, supporting its use for alleviating rhinitis symptoms associated with AC.<br />Competing Interests: Disclosure MEC and JIW are employees of Bausch … Lomb Incorporated. PJG is an employee of Ora. The authors report no other conflicts of interest in this work.
Details
- Language :
- English
- ISSN :
- 1178-6965
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Journal of asthma and allergy
- Publication Type :
- Academic Journal
- Accession number :
- 29615844
- Full Text :
- https://doi.org/10.2147/JAA.S160687